Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children

Sarah Ronaldson,1 Matthew Taylor,1 Peter G Bech,2 Ruth Shenton,1 Albrecht Bufe3 1York Health Economics Consortium, York, UK; 2ALK-Abelló A/S, Hørsholm, Denmark; 3Ruhr-Universität Bochum, Bochum, Germany Background: Grass pollen-induced rhinoconjunctivitis is a common...

Full description

Bibliographic Details
Main Authors: Ronaldson S, Taylor M, Bech PG, Shenton R, Bufe A
Format: Article
Language:English
Published: Dove Medical Press 2014-04-01
Series:ClinicoEconomics and Outcomes Research
Online Access:http://www.dovepress.com/economic-evaluation-of-sq-standardized-grass-allergy-immunotherapy-tab-a16384
_version_ 1818936357284741120
author Ronaldson S
Taylor M
Bech PG
Shenton R
Bufe A
author_facet Ronaldson S
Taylor M
Bech PG
Shenton R
Bufe A
author_sort Ronaldson S
collection DOAJ
description Sarah Ronaldson,1 Matthew Taylor,1 Peter G Bech,2 Ruth Shenton,1 Albrecht Bufe3 1York Health Economics Consortium, York, UK; 2ALK-Abelló A/S, Hørsholm, Denmark; 3Ruhr-Universität Bochum, Bochum, Germany Background: Grass pollen-induced rhinoconjunctivitis is a common allergic respiratory disorder affecting over 20% of the UK population in terms of quality of life and sleep, work, and school patterns. The SQ-standardized grass allergy immunotherapy tablet (AIT) has been demonstrated as a disease-modifying treatment which gives a sustained effect even after completion of a treatment course. The objective of this study was to provide an economic assessment of whether treatment with the SQ-standardized grass AIT, Grazax® (Phleum pratense) in combination with symptomatic medications is preferable to the standard of care using symptomatic medications only. The analysis was performed for children with grass pollen-induced rhinoconjunctivitis, with or without concomitant asthma, in the UK. Methods: The model evaluated the two treatment regimens in a cohort of 1,000 children from a payer’s perspective. Treatment was modeled in terms of management of symptoms, impact on resource use, and development of allergic asthma. The analysis modeled the use of SQ-standardized grass AIT and the sustained effects of treatment over a 9-year time horizon (ie, 3 years of treatment, with modeled long-term benefits). Data inputs were drawn from a recent clinical trial, published studies, and databases. Results: SQ-standardized grass AIT improves patient outcomes, generating an incremental cost per quality-adjusted life year gained of £12,168. This is below commonly accepted thresholds in the UK. Conclusion: The resulting incremental cost per QALY falls below commonly accepted willingness to pay thresholds. Therefore, the SQ-standardized grass AIT is a cost-effective option for the treatment of grass pollen-induced rhinoconjunctivitis in the UK pediatric population. Keywords: cost-effectiveness, cost, quality of life, cost-benefit, United Kingdom, rhinoconjunctivitis, infant
first_indexed 2024-12-20T05:34:47Z
format Article
id doaj.art-8f636fad33ab44aa8a46974cc283de65
institution Directory Open Access Journal
issn 1178-6981
language English
last_indexed 2024-12-20T05:34:47Z
publishDate 2014-04-01
publisher Dove Medical Press
record_format Article
series ClinicoEconomics and Outcomes Research
spelling doaj.art-8f636fad33ab44aa8a46974cc283de652022-12-21T19:51:39ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812014-04-012014default18719616384Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in childrenRonaldson STaylor MBech PGShenton RBufe ASarah Ronaldson,1 Matthew Taylor,1 Peter G Bech,2 Ruth Shenton,1 Albrecht Bufe3 1York Health Economics Consortium, York, UK; 2ALK-Abelló A/S, Hørsholm, Denmark; 3Ruhr-Universität Bochum, Bochum, Germany Background: Grass pollen-induced rhinoconjunctivitis is a common allergic respiratory disorder affecting over 20% of the UK population in terms of quality of life and sleep, work, and school patterns. The SQ-standardized grass allergy immunotherapy tablet (AIT) has been demonstrated as a disease-modifying treatment which gives a sustained effect even after completion of a treatment course. The objective of this study was to provide an economic assessment of whether treatment with the SQ-standardized grass AIT, Grazax® (Phleum pratense) in combination with symptomatic medications is preferable to the standard of care using symptomatic medications only. The analysis was performed for children with grass pollen-induced rhinoconjunctivitis, with or without concomitant asthma, in the UK. Methods: The model evaluated the two treatment regimens in a cohort of 1,000 children from a payer’s perspective. Treatment was modeled in terms of management of symptoms, impact on resource use, and development of allergic asthma. The analysis modeled the use of SQ-standardized grass AIT and the sustained effects of treatment over a 9-year time horizon (ie, 3 years of treatment, with modeled long-term benefits). Data inputs were drawn from a recent clinical trial, published studies, and databases. Results: SQ-standardized grass AIT improves patient outcomes, generating an incremental cost per quality-adjusted life year gained of £12,168. This is below commonly accepted thresholds in the UK. Conclusion: The resulting incremental cost per QALY falls below commonly accepted willingness to pay thresholds. Therefore, the SQ-standardized grass AIT is a cost-effective option for the treatment of grass pollen-induced rhinoconjunctivitis in the UK pediatric population. Keywords: cost-effectiveness, cost, quality of life, cost-benefit, United Kingdom, rhinoconjunctivitis, infanthttp://www.dovepress.com/economic-evaluation-of-sq-standardized-grass-allergy-immunotherapy-tab-a16384
spellingShingle Ronaldson S
Taylor M
Bech PG
Shenton R
Bufe A
Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children
ClinicoEconomics and Outcomes Research
title Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children
title_full Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children
title_fullStr Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children
title_full_unstemmed Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children
title_short Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax®) in children
title_sort economic evaluation of sq standardized grass allergy immunotherapy tablet grazax reg in children
url http://www.dovepress.com/economic-evaluation-of-sq-standardized-grass-allergy-immunotherapy-tab-a16384
work_keys_str_mv AT ronaldsons economicevaluationofsqstandardizedgrassallergyimmunotherapytabletgrazaxreginchildren
AT taylorm economicevaluationofsqstandardizedgrassallergyimmunotherapytabletgrazaxreginchildren
AT bechpg economicevaluationofsqstandardizedgrassallergyimmunotherapytabletgrazaxreginchildren
AT shentonr economicevaluationofsqstandardizedgrassallergyimmunotherapytabletgrazaxreginchildren
AT bufea economicevaluationofsqstandardizedgrassallergyimmunotherapytabletgrazaxreginchildren